フォートリアとオミコ、バイオマーカー主導の抗がん剤開発推進に向けて提携

Fortrea, a leading clinical development CRO, has partnered with Omico, Australia's precision oncology screening organization, to accelerate biomarker-driven cancer clinical trials. The collaboration combines Fortrea's oncology trial expertise with Omico's PrOSPeCT platform to improve trial site selection, patient matching, and recruitment efficiency in Australia, with plans to expand globally.